Details
Description
This analysis performed signal identification for Ozempic (a specific form of semaglutide) by monitoring non-pregnancy and non-cancer outcomes among new users of Ozempic compared to new users of sitagliptin among type 2 diabetics.
The study period includes data from January 1, 2018 to February 28, 2022.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.